Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report describes an adult female with congenital adrenal hyperplasia who developed secondary amenorrhea and hair loss due to androgen overproduction from ovarian adrenal rests, detectable only after pelvic venous sampling, and normalizing after unilateral oophorectomy.

This study found that despite androgen excess and genitourinary masculinization, adult women with congenital adrenal hyperplasia did not exhibit notable prostatic growth.

This review discusses current and evolving treatment strategies for congenital adrenal hyperplasia in adolescents and adults, focusing on glucocorticoid and mineralocorticoid therapy and the management of insulin resistance, without reporting new clinical results.

A gene mutation in mice causes increased mast cells and disorganized hair follicles in their skin.

The authors concluded that plasma levels of 3α-diolG, ADTG, and DHTG in women with hyperandrogenic disorders primarily reflect adrenal androgen contributions rather than peripheral action, suggesting a potential index for treatment effectiveness.

In this study, researchers found that the microRNA miR-1199-5p may reduce the expression of SRD5A2 in benign prostatic hyperplasia tissues, potentially contributing to the failure of 5-α reductase inhibitor therapy in some patients.

This study found that Caesalpinia bonduc seed extracts significantly reduced prostate weight and improved prostate tissue morphology in Wistar rats with testosterone-induced benign prostatic hyperplasia.

Men using 5-alpha reductase inhibitors for prostate issues may have a slightly higher risk of blood clots.

This review discusses sexual dysfunction as a potential side effect of drugs for Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms and reports no new clinical results; it emphasizes the need for methodologically robust studies.

This study suggests that using both finasteride and dutasteride may increase the risk of acute coronary syndrome in patients with benign prostate hyperplasia.

Untreated Congenital Adrenal Hyperplasia can cause severe hair loss due to high androgen levels.

This study found that Tripterygium wilfordii multiglycoside significantly inhibited testosterone-induced benign prostatic hyperplasia in rats without causing toxicity, suggesting its potential as a therapy for BPH.

This case report suggests that Roux-en-Y gastric bypass may improve symptoms of non-classic adrenal hyperplasia related to 11-hydroxylase deficiency by reducing insulin resistance.

This article discusses androgenetic alopecia as a potential early marker for benign prostatic hyperplasia but reports no new clinical findings.

This case study reports that a woman with non-classical adrenal hyperplasia who self-treated with Ashwagandha for six months experienced biochemical improvements and reduced scalp hair loss.

This study found that the petroleum ether extract of Citrullus colocynthis fruit and an isolated steroidal compound may reduce prostatic hyperplasia in rats induced by testosterone, suggesting potential use in managing androgen-dependent conditions.

This study found that while new treatments like Optilume, Rezum, and Aquablation have minimal risks of sexual dysfunction, they offer less improvement in lower urinary tract symptoms compared to traditional surgeries like TURP, though Aquablation does reduce ejaculatory dysfunction more effectively than TURP.

This study found that treating dogs with benign prostatic hyperplasia using osaterone acetate reduced prostatic volume and increased diffusion times of an ultrasound contrast agent, suggesting effective treatment and potential for CEUS monitoring.

This review discusses various treatment options for non-classic congenital adrenal hyperplasia due to 21α-hydroxylase and 11β-hydroxylase deficiencies without providing new clinical results.

In this study, dihydroartemisinin reduced prostate enlargement and related markers in a rat model of benign prostatic hyperplasia, suggesting its potential as a therapeutic agent.

In this study, the authors observed that treatment patterns for new benign prostatic hyperplasia largely aligned with guidelines, but 5-α reductase inhibitors were used inappropriately based on prostate size as indicated by prostate specific antigen.

This study found that lower urinary tract symptoms in older men with benign prostatic hyperplasia negatively impact sexual function and mental health, suggesting the importance of early intervention to improve quality of life.

This study found that LHE may prevent and reverse testosterone-induced prostatic hyperplasia, supporting the traditional use of Kigelia africana for some reproductive system disorders.

This study found that measuring certain steroids in hair can help diagnose and monitor congenital adrenal hyperplasia in Indonesian patients, offering a simple noninvasive method for developing countries.

This review discusses imaging's role in the diagnosis and management of congenital adrenal hyperplasia and reports no new clinical results; it suggests a potential presentation route via incidental radiologic findings.

This study found that Medicare patients with benign prostatic hyperplasia had high adherence to 5-alpha reductase inhibitor therapy, which was associated with a reduced risk of needing surgical intervention.

The abstract discusses that Serenoa repens, a commonly used phytotherapeutic agent, may play a crucial role as an alternative or complementary treatment for lower urinary tract symptoms in patients with benign prostatic hyperplasia, particularly those with mild-to-moderate disease severity.

This study found no relationship between androgenic alopecia and parameters such as PSA level, IPSS, and prostate volume in men over 50.

This study found that diagnosing non-classical 3 beta-hydroxysteroid dehydrogenase deficiency solely based on elevated serum or urinary 5-ene-steroids may not be reliable.